SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Weber, M. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weber, M. A
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

Michael A Weber

State University of New York Downstate College of Medicine, Brooklyn, New York, USA, Michaelwebermd{at}cs.com

The ability of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) to lower blood pressure (BP) is well established. ACE inhibitors (ACE-Is) have also been shown to improve the prognosis of a broad range of patients at high cardiovascular risk, including those with heart failure, post-myocardial infarction (MI), and nephropathy. These benefits suggest that interrupting the reninangiotensin-aldosterone system (RAAS) with ACE-Is has a widespread vasculoprotective effect, provided that BP is also adequately controlled. Evidence that RAAS blockade by ARBs also improves long-term clinical outcomes in patients with cardiovascular disease has started to accumulate, and will be tested further during the coming years as a number of large-scale, prospective trials are completed. These trials are investigating the long-term protective effects of ARBs on morbidity and mortality in patients with hypertension, heart failure, diabetes mellitus, acute MI, or established vascular disease. The results should establish the extent to which ARBs exhibit the vasculoprotective properties demonstrated by ACE-Is in patients at high cardiovascular risk. If ARBs are found to provide benefits that are similar to , or even greater than ACE-Is, it may have important implications for drug selection, given the excellent tolerability of ARBs. Some studies are also investigating whether more extensive RAAS blockade using a combination of an ARB and an ACE-I will offer even greater protection than either agent alone.

Key Words: angiotensin II receptor blocker • ACE inhibitor • outcome trials • renin-angiotensin-aldosterone system • cardiovascular protection

References

  • Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-71.[Abstract/Free Full Text]
  • Bonner G. The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors. Drugs 1997;54:23-30.
  • Israili ZH, Hall WD Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy.A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.[Abstract/Free Full Text]
  • Ennezat PV, Berlowitz M., Sonnenblick EH, Le Jemtel TH Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000;2:258-62.[Medline] [Order article via Infotrieve]
  • Goa KL, Wagstaff AJ Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996;51:820-45.[Web of Science][Medline] [Order article via Infotrieve]
  • McClellan KJ, Goa KL Candesartan cilexetil.A review of its use in essential hypertension. Drugs 1998;56:847-69.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Markham A., Goa KL Valsartan.A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299-311.[Web of Science][Medline] [Order article via Infotrieve]
  • Sharpe M., Jarvis B., Goa KL Telmisartan: a review of its use in hypertension. Drugs 2001;61:1501-29.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McClellan KJ, Balfour JA Eprosartan. Drugs 1998; 55:713-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gardner SF, Franks AM Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann Pharmacother 2003;37:99-105.[Abstract/Free Full Text]
  • Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997;54:885-902.[Web of Science][Medline] [Order article via Infotrieve]
  • Grossman E., Messerli FH, Neutel JMAngiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch Intern Med 2000;160:1905-11.[Free Full Text]
  • Pylypchuk GB ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998;32:1060-6.[Abstract]
  • Dahlöf B., Devereux R., de Faire U. et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. Am J Hypertens 1997;10:705-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hansson L., Lithell H., Skoog I. et al. Study on Cognition and Prognosis in the Elderly (SCOPE): baseline characteristics. Blood Press 2000;9:146-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hansson L., Lithell H., Skoog I. et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999;8:177-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mann J., Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176-83.
  • Pitt B., Chang P.,Timmermans Pbmwm. Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovasc Drugs Ther 1995;9:693-700.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Segal R., Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Poole-Wilson P., Segal R. et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study - ELITE II. J Card Fail 1999;5:146-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Poole-Wilson P., Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohn JN, Tognoni G., Glazer RD, Spormann D., Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999;5:155-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohn JN, Tognoni G., Glazer R., Spormann D., for the Val-HeFT Investigators. Baseline demographics of the Valsartan Heart Failure Trial. Eur J Heart Fail 2000;2:439-46.[Abstract/Free Full Text]
  • Cohn JN, Tognoni G., for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-75.[Abstract/Free Full Text]
  • Tsuyuki RT,Yusuf S., Rouleau JL et al. Combination neuro-hormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997;13:1166-74.[Web of Science][Medline] [Order article via Infotrieve]
  • Swedberg K., Pfeffer M., Granger C. et al. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999;5:276-82.[CrossRef][Medline] [Order article via Infotrieve]
  • Brenner BM, Cooper ME, de Zeeuw D. et al. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). JRAAS 2000; 1:328-35.[Medline] [Order article via Infotrieve]
  • Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
  • Parving HH, Lehnert H., Bröchner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-8.[Abstract/Free Full Text]
  • Rodby RA, Rohde RD, Clarke WR et al.The Irbesartan Type II Diabetic NephropathyTrial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000;15:487-97.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
  • Toto R. Angiotensin II subtype receptor blockers and renal function. Arch Intern Med 2001;161:1492-9.[Abstract/Free Full Text]
  • Rippin J., Bain SC, Barnett AH Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. J Diabetes Complications 2002;16:195-200.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dickstein K., Kjekshus J., for the OPTIMAAL Study Group. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Am J Cardiol 1999;83:477-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pfeffer MA, McMurray J., Leizorovicz A. et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pfeffer MA Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers. Am Heart J 2000;139(1 Pt 2):S23-S28.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yusuf S. From HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002;89:18A-25A.[Web of Science][Medline] [Order article via Infotrieve]
  • Kannel WB Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens 1991;9(suppl 2):S3-S8.
  • Carson P., Giles T., Higginbotham M., Hollenberg N., Kannel W., Siragy HM Angiotensin receptor blockers: evidence for preserving target organs. Clin Cardiol 2001;24:183-90.[Web of Science][Medline] [Order article via Infotrieve]
  • Dahlöf B., Devereux RB, Julius S. et al. Characteristics of 9194 patients with left ventricular hypertrophy.The LIFE study. Hypertension 1998;32:989-97.[Abstract/Free Full Text]
  • Dahlöf B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Polidori MC, Marvardi M., Cherubini A., Senin U., Mecocci P. Heart disease and vascular risk factors in the cognitively impaired elderly: implications for Alzheimer's dementia. Aging (Milano) 2001;13:231-9.[Medline] [Order article via Infotrieve]
  • Birkenhager WH, Forette F., Seux ML, Wang JG, Staessen JA Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 2001;161:152-6.[Abstract/Free Full Text]
  • MacMahon S., Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993;15:967-78.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.[Abstract]
  • The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.[Abstract]
  • The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.[Abstract]
  • McKelvie RS,Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999; 100:1056-64.[Abstract/Free Full Text]
  • UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-62.[Abstract/Free Full Text]
  • Mann JF, Gerstein HC, Pogue J., Bosch J.,Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.[Abstract/Free Full Text]
  • Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. Diabetologia 1996;39:1646-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N., Schrier RW The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.[Abstract/Free Full Text]
  • The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996;12:127-37.[Web of Science][Medline] [Order article via Infotrieve]
  • The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
  • Dagenais GR,Yusuf S., Bourassa MG et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001; 104:522-6.[Abstract/Free Full Text]
  • Unger T., Chung O., Csikos T. et al.Angiotensin receptors. J Hypertens 1996;14(suppl 5):S95-S103.[CrossRef]
  • de Gasparo M., Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensinconverting enzyme? Pharmacol Toxicol 1998;82:257-71.[Web of Science][Medline] [Order article via Infotrieve]
  • Wienen W.,Hauel N., van Meel JC,Narr B., Ries U., Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993;110:245-52.[Web of Science][Medline] [Order article via Infotrieve]
  • Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998;15:206-17.[Web of Science]
  • Lacourcière Y., Lenis J., Orchard R. et al.A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998;3:295-302.[Medline] [Order article via Infotrieve]
  • Karlberg BE, Lins L.-E, Hermansson K., for the TEES Study Group. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999;17:293-302.[Web of Science][Medline] [Order article via Infotrieve]
  • Mallion JM, Siché JP, Lacourcière Y., the Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13: 657-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Littlejohn T., Mroczek W., Marbury T., VanderMaelen CP, Dubiel RFA prospective, randomized, open-label trial comparing telmisartan 80 mg and valsartan 80 mg in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000;16:1123-32.[Web of Science][Medline] [Order article via Infotrieve]
  • Neutel JM, Kolloch RE, Plouin PF Comparison of telmisartan monotherapy with losartan + HCTZ in mild-to-moderate hypertension. Am J Hypertens 2000;13:58A-9A [abstract].
  • White WB Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001;6:63-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998;15:229-40.[Web of Science]
  • Lacourcière Y., the Telmisartan Cough Study Group. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Int J Clin Pract 1999;53:99-103.[Web of Science][Medline] [Order article via Infotrieve]
  • Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83.[Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 2, 62-73 (2003)
DOI: 10.3317/jraas.2003.015
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
B. J Epstein and J. G Gums
Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations
Ann. Pharmacother., March 1, 2005; 39(3): 470 - 480.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Weber, M. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weber, M. A
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement